Why the study?
Do antiplatelet agents (aspirin, clopidogrel, cilostazol) reduce circulating tissue factor procoagulant activity in patients with peripheral arterial disease?
Population
26 patients with lower extremity peripheral arterial disease (PAD), mean age 65.9 +/- 8.4 years
Comparison
Sequential two-week treatment regimens with… vs Baseline levels and healthy control subjects
Design
Cohort
Follow-up
two-week treatment regimens
Authors
Loading...
Clopidogrel-based regimens were associated with TF-PCA reduction in PAD; hypothesis-generating for mechanisms beyond platelet inhibition and requires randomized confirmation.
Do antiplatelet agents (aspirin, clopidogrel, cilostazol) reduce circulating tissue factor procoagulant activity in patients with peripheral arterial disease?
Antiplatelet therapy, particularly clopidogrel-based regimens, reduces circulating tissue factor procoagulant activity in patients with peripheral arterial disease, suggesting an additional antithrombotic and proinflammatory mechanism beyond platelet aggregation inhibition.
Vaidyula et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: